Abstract 173P
Background
This retrospective multicenter real-world study aims to compare outcomes reached by L and S second-line therapy in HCC patients treated with first-line AB.
Methods
The overall cohort included 891 HCC patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea) treated with AB in first-line setting between October 2018 and April 2022. A total of 472 (53.0%) patients had progressive disease after first-line therapy, of which 243 (51.5%) received a second-line treatment. Data from 137 patients were available for the analysis: 51 (37.2%) received S and 86 (62.8%) L.
Results
L second-line subgroup achieved a median overall survival (mOS) of 18.9 months, significative longer (p = 0.01; HR: 2.24) compared to S subgroup that reached a mOS of 14.3 months. After adjusting for positive clinical covariates at univariate analysis, multivariate analysis highlighted Albumin-Bilirubin (ALBI) 1 grade [p < 0.01; hazard ratio (HR): 5.23] and L second-line therapy (p = 0.01; HR: 2.18) as positive prognostic factor for OS. Forest plot highlighted a positive trend in terms of OS in favor of patients treated with L second-line regardless of baseline characteristics before first-line therapy. In particular, L second-line subgroup had a better OS compared to S second-line subgroup in male patients, aged ≤ 70 years, with viral etiology, Barcelona Clinic Liver Cancer C stage, αfetoprotein < 400 ng/mL, Child-Pugh A, NLR < 3, ALBI 1 grade, performance status ≤ 1, presence of portal vein thrombosis. Regarding first-line treatment outcomes, L second-line subgroup achieved a median progression-free survival (mPFS) of 3.5 months, while S second-line subgroup reached a mPFS of 4.3 months without any significative difference (p 0.42; HR: 1.15). There was no difference in overall response rate (L 26.1% vs. S 19.8%; p = 0.29) and disease control rate (L 76.8% vs. S 66.4%; p = 0.71) between the two subgroups.
Conclusions
L second-line therapy is superior to S in HCC patients progressed to first-line AB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract